Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Department of Surgery, Division of Surgical Oncology, Oregon Health Sciences University, Portland, Oregon, USA.
J Surg Oncol. 2021 Mar;123(4):949-956. doi: 10.1002/jso.26370. Epub 2021 Jan 5.
The main surgical approach to patients with localized intrahepatic cholangiocarcinoma (ICC) is hepatectomy, but transplantation has been described. A comparison of outcomes between these surgical approaches is necessary to determine if one is preferable.
Patients with ICC were identified using the National Cancer Database (2010-2016). Patients were grouped based on operation and matched 1:1 by propensity score. Pathologic and postoperative outcomes, as well as overall survival were analyzed.
There were 1879 hepatectomy and 74 liver transplantation patients. Before matching, transplantation patients were younger and more often treated at academic centers. More patients who underwent a transplantation received neoadjuvant chemotherapy (70.3% vs. 12.8%). Patients who underwent transplantation had more pathologic T0 (7.7% vs. 0.4%) and T1 (47.7% vs. 42.1%) tumors (p < .001). There were no differences in length of stay, unplanned readmissions, 30/90-day mortality, or median survival between groups (36.1 vs. 36.1 months, p = .34). After matching (n = 57/group), there were no differences in postoperative outcomes or survival between transplantation or hepatectomy (36.1 vs. 33.6 months, p = .57).
Among patients with ICC, hepatectomy and liver transplantation were associated with similar postoperative outcomes and survival. In light of the resources and chronic immunosuppression required for transplantation, hepatectomy seems preferable for localized ICC.
局部肝内胆管癌(ICC)患者的主要手术方法是肝切除术,但也有报道称可以进行肝移植。为了确定哪种方法更优,有必要比较这两种手术方法的结果。
使用国家癌症数据库(2010-2016 年)确定 ICC 患者。根据手术将患者分组,并通过倾向评分进行 1:1 匹配。分析病理和术后结果以及总生存率。
共有 1879 例肝切除术和 74 例肝移植患者。在匹配之前,肝移植患者更年轻,并且更多地在学术中心接受治疗。更多接受肝移植的患者接受了新辅助化疗(70.3%比 12.8%)。接受移植的患者有更多的病理 T0(7.7%比 0.4%)和 T1(47.7%比 42.1%)肿瘤(p < .001)。两组之间的住院时间、非计划再入院、30/90 天死亡率或中位生存时间没有差异(36.1 比 36.1 个月,p = .34)。在匹配(n = 57/组)后,肝移植或肝切除术之间的术后结果或生存无差异(36.1 比 33.6 个月,p = .57)。
在 ICC 患者中,肝切除术和肝移植与相似的术后结果和生存相关。鉴于肝移植需要的资源和慢性免疫抑制,肝切除术似乎更适合局部 ICC。